the benefits of glp 1 drugs beyond obesity GLP-1 and health: weight loss in Ozempic era GLP-1 drugs calm inflammation beyond

GLP-1RAs inhibit the activation of the NLRP3 inflammasome signaling pathway to regulate mouse renal podocyte pyroptosis

doi: 10.1042/bj2070381

Wegovy is specifically approved for chronic weight management, while Ozempic is primarily used for managing type 2 diabetes (though it may be prescribed off-label for weight loss)

Several mid-stage trials will read out in 2025 to provide important proof points for novel MoAs and their potential for differentiation, e.g., Lillys bimagrumab (activin/myostatin type II receptor inhibitor) in combination with semaglutide, aiming to deliver weight loss while preserving muscle mass (phase 2b)

[DOI] [PubMed] [Google Scholar] 159.Yang R., Zhang L., Guo J., Wang N., Zhang Q., Qi Z., Wu L., Qin L., Liu T